Loss of E-cadherin is a key initial step in the transdifferentiation of epithelial cells to a mesenchymal phenotype, which occurs when tumor epithelial cells invade into surrounding tissues. Expression of the nuclear factor ZEB1 induces an epithelial-to-mesenchymal transition and confers a metastatic phenotype on carcinomas by repressing the E-cadherin gene at the transcriptional level.
Introduction
Invasion of carcinomas into surrounding tissues and their eventual metastasis requires that epithelial cells undergo a de-differentiation process known as epithelial-mesenchymal transition (EMT) (Polyak and Weinberg, 2009) . During the EMT, epithelial cells lose their polarity and intercellular adhesion and acquire a mesenchymal phenotype with higher motility. A hallmark event in the EMT is the downregulation/loss of the E-cadherin adhesion protein. Dissecting the molecular mechanisms that regulate E-cadherin expression has therefore become pivotal for understanding tumor invasiveness and metastasis.
E-cadherin expression is regulated at multiple levels having been described carcinomas with genetic, epigenetic, transcriptional and post-translational alterations of the E-cadherin (Peinado et al., 2007) . At the transcriptional level E-cadherin is repressed by a number of nuclear factors (E-cadherin transcriptional repressors, EcTRs) such as ZEB1 (also known as dEF1, zfhx1a), ZEB2 (SIP1, zfhx1b), SNAI1 (Snail), SNAI2 (Slug), E12/E47 and Twist1/2. Expression of these EcTRs in tumor epithelial cells is inversely correlated with E-cadherin and associates with increased invasiveness/metastasis and poorer clinical prognosis (MorenoBueno et al., 2008) .
EMT may also be linked with the generation of cancer stem cells in epithelial tumors (Rosen and Jordan, 2009; Peter, 2010) . Stem cells from epithelial organs and carcinomas show a mesenchymal phenotype characterized by high levels of EcTRs. In turn, overexpression of EcTRs not only induces a stem cell antigenic phenotype but also increases the number of cells with the capacity of seeding new tumors .
ZEB1 is a transcription factor that controls key regulatory genes during embryonic development and cell differentiation (Vandewalle et al., 2009) . Among them, ZEB1 represses E-cadherin transcription by binding to two E box sequences in its promoter region (Grooteclaes and Frisch, 2000; Eger et al., 2005; Shirakihara et al., 2007) . Expression of ZEB1 in epithelial cells induces an EMT and promotes tumor invasiveness in in vitro and in vivo models (Aigner et al., 2007; Spaderna et al., 2008) . Furthermore, mice with a targeted deletion of the ZEB1 gene show ectopic expression of E-cadherin and loss of mesenchymal genes such as vimentin (Liu et al., 2008) .
Expression of ZEB1 is upregulated by mechanisms known to activate EMT such as transforming growth factor-b, nuclear factor-kB, hypoxia and SNAI1 (reviewed in Peinado et al., 2007) , and repressed by noncoding RNAs of the miR-200 and miR-205 families, known to induce epithelial differentiation (Gregory et al., 2008; Park et al., 2008) . In turn, ZEB1 transcriptionally represses miR-200 family members thus creating an EMT regulatory loop in ZEB1-expressing tumors (Burk et al., 2008) . Repression of miR200c, miR203 and miR183 by ZEB1 is also required for maintenance of a stem cell phenotype further supporting a link, mediated by ZEB1/miR, between EMT and cancer stem cells (Wellner et al., 2009; Peter, 2010) . ZEB1 could also contribute to overcome oncogenic addiction in tumors-ZEB1 is expressed in K-rasindependent cancer lines and its elimination induces K-ras dependency (Singh et al., 2009) .
ZEB1 represses transcription by recruiting the CtBP corepressor to its CtBP-interacting domain (CID) (see scheme in Figure 2a ; Furusawa et al., 1999; Postigo and Dean, 1999a; Chinnadurai, 2007) and CtBP has been involved in ZEB1-mediated repression of E-cadherin (Grooteclaes and Frisch 2000; Shi et al., 2003) . Nevertheless, it has been reported that, at least in 293T cells, ZEB1 could repress E-cadherin through CtBP-independent mechanisms yet to be determined (van Grunsven et al., 2003) and addressed in the present paper.
Although loss of BRG1 and/or BRM-the two mutually exclusive ATPase subunits of the SWI/SNF chromatin-remodeling complex-is found in a number of cancer lines and primary tumors (Reisman et al., 2009) , expression of BRG1, but not of BRM, has also been correlated with higher invasive/metastatic behavior in carcinomas (Sentani et al., 2001; Sun et al., 2007) . BRG1 associates with DNA-binding transcription factors and histone-modifying enzymes to activate/repress transcription as well as to regulate DNA replication, repair and recombination (Trotter and Archer, 2008) .
In this report, we show that ZEB1 interacts with BRG1 to repress the E-cadherin promoter. ZEB1 and BRG1 colocalize in vivo in E-cadherin-negative cells from established lines, and stroma of normal colon as well as in de-differentiated epithelial cells at the invasion front of colorectal carcinomas. Our results show that BRG1 is required for the regulation E-cadherin and the induction of EMT by ZEB1.
Results
Differential pattern of E-cadherin repression by ZEB1 across cell lines As indicated above, it has been suggested that ZEB1 could repress E-cadherin via CtBP-independent mechanism(s). To elucidate such alternative mechanisms, we tested the ability of ZEB1 and a CID-mutant form of ZEB1 (ZEB1 CIDm , which is unable to bind CtBP) to repress transcription of the E-cadherin promoter in a panel of carcinoma cell lines. We found that in MCF7, SW480, 293T, HCT116 and Hs578T ( Figure 1a and data not shown) mutation of the CID region resulted in only a partial relief of ZEB1-mediated repression thus supporting the existence of alternative repressor mechanisms. However, when similar experiments were carried out in SW13 and C33a cells, not only did wild-type ZEB1 showed a lower repressor activity than in the other cell lines but mutation of the CID region was sufficient to abrogate ZEB1-mediated repression (Figure 1b) .
The repressor effect of ZEB1 CIDm in MCF7 and SW480 but not in SW13 and C33a cells prompted us to hypothesize that the latter cell lines may lack some corepressor factor(s), different from CtBP but important for ZEB1 regulation of E-cadherin. Interestingly, SW13 and C33 cells-but not the other lines tested abovehave been described as deficient in the two ATPases of the SWI/SNF-remodeling complex, BRG1 and BRM (Zhang et al., 2000) . This observation led us to analyze whether these two proteins may be involved in the repression of E-cadherin by ZEB1.
ZEB1 interacts with BRG1
We therefore started testing whether ZEB1 interacts with BRG1 by coexpressing tagged versions of both proteins in 293T cells followed by their co-immunoprecipitation. The cell-cycle protein Geminin, which is known to bind BRG1 and BRM (Seo et al., 2005) , was used as a positive control. This experiment revealed that ZEB1 was able to bind BRG1 (Figure 2b and Supplementary Figure A) .
To confirm that the interaction between ZEB1 and BRG1 also occurs without overexpression, we carried out two-way co-immunoprecipitation experiments in cell lysates from 293T that express ZEB1 and BRG1 endogenously. Immunoprecipitation with an anti-ZEB1 antibody specifically pulled down endogenous BRG1 and, conversely, an anti-BRG1 antibody co-immunoprecipitated endogenous ZEB1 (Figure 2c ). These results indicate that ZEB1 and BRG1 are indeed capable of interacting to form an endogenous complex.
ZEB1 is a highly modular protein and separate domains have been identified for its interaction with DNA as well as with a number of proteins such as CtBP, Smad2/3 and p300 (Postigo and Dean 1997, 1999a, b; Furusawa et al., 1999; Postigo 2003) (Figure 2a ). We therefore sought to define the region within ZEB1 that mediates the interaction with BRG1. To this end, we generated three tagged fragments of ZEB1 encompassing its C-terminal (CtR), central (CR) and N-terminal (NtR) regions and co-expressed them in 293T along with full-length BRG1. As shown in Figure 2d (and Supplementary Figure B) , the NtR of ZEB1, but not the other two regions, bound to BRG1. As CID is located in the CR, BRG1 and CtBP appear to interact through different regions within ZEB1.
ZEB1 and BRG1 colocalize in vivo at the invasion front of carcinomas We next wondered whether ZEB1 and BRG1 colocalize in living cells. Indeed, confocal microscopy and spectral analysis in E-cadherin-negative SW480 cells, revealed the colocalization of both proteins with identical matching patterns of nuclear condensation (Supplementary Figure C ). Colocalization of ZEB1 and BRG1 was also detected in E-cadherin-negative cells located in the stromal compartment of normal colon tissue ( Figure 3a and Supplementary Figure D) .
At the membrane of normal epithelial cells E-cadherin associates with the oncoprotein b-catenin (Peinado et al., 2007) . Although b-catenin maintains its membranous/cytoplasmic expression at the center of a carcinoma, just as it does in normal epithelium, it translocates to the nucleus in isolated and scattered E-cadherin-negative Repression of E-cadherin by ZEB1/BRG1 E Sánchez-Tilló et al dedifferentiated epithelial cells present at the tumor front (Brabletz et al., 1998 (Brabletz et al., , 2002 . As cells at the invasive edge of colorectal carcinomas are undergoing active EMT, we decided to examine the colocalization of ZEB1 and BRG1 at the tumor front ( Figure 3b and Supplementary Figure D) . ZEB1 is absent in differentiated epithelial cells but expressed in those scattered cells at the tumor front. Importantly, ZEB1 and BRG1 only colocalize in these E-cadherin-negative and invasive undifferentiated epithelial cells expressing nuclear b-catenin (note the white/pink staining in the merged panel of Figure 3b and Supplementary Figure D) .
BRG1 acts as a corepressor of ZEB1 to regulate E-cadherin transcription
We then analyzed whether an endogenous ZEB1/BRG1 complex (as shown in Figure 2c ) could be assembled onto the E-cadherin promoter. In chromatin immunoprecipitation assays, we found that ZEB1 and BRG1 bind to a fragment of the E-cadherin promoter containing the ZEB1-binding sites (Figure 4a , left panel). Knocking down of ZEB1 with specific small interfering RNA (siRNA) not only blocked binding of ZEB1 to E-cadherin but also that of BRG1 (Figure 4a , right panel), indicating that the recruitment of the latter to E-cadherin takes place through a ZEB1-dependent mechanism. Next, we analyzed whether the formation of a ZEB1/ BRG1 complex onto the E-cadherin promoter could regulate its transcription. To this end, we expressed the E-cadherin promoter along both proteins in MCF7 cells, which are defective for ZEB1 but positive for BRG1. Overexpression of BRG1 (or highly related BRM) alone did not have any significant effect on the basal activity of the E-cadherin promoter (Figure 4b and Supplementary Figure E) . As expected, ZEB1 repressed the E-cadherin promoter but its repressor effect was enhanced the overexpression of BRG1 but not by that of BRM. By contrast, knock down of endogenous BRG1 with specific siRNA alleviated ZEB1-mediated repression (Figure 4b ).
To elucidate whether BRG1 co-repressor activity is dependent on CtBP binding to ZEB1, we carried out experiments similar as those in Figure 4b but using ZEB1 CIDm instead of wild-type ZEB1. Although ZEB1-CIDm is not as efficient repressor of E-cadherin its effect was heightened by the overexpression of BRG1 (Figure 4c , left panel), while elimination of endogenous BRG1 with siRNA almost totally rescued its repressor activity (Figure 4c , right panel). Taken together, these results indicate that BRG1 not only synergizes with ZEB1 in the repression of the E-cadherin promoter, but also, that its co-repressor role could take place in the absence of CtBP. Furthermore, the fact that knock down of BRG1 rendered ZEB1 CIDm into a non-repressor construct suggests that CtBP and BRG1 are the main, indeed perhaps the only, co-repressor mechanisms by which ZEB1 regulates the E-cadherin promoter.
The above experiments prompted us to further examine the role of ZEB/BRG1 complexes by using a Repression of E-cadherin by ZEB1/BRG1 E Sánchez-Tilló et al cell system where BRG1 was missing. Exogenous expression of BRG1 in C33a cells enhanced the ability of ZEB1 and ZEB1 CIDm to inhibit the E-cadherin promoter ( Figure 4d ). As the NtR of ZEB1 mediates interaction with BRG1, we generated a form of ZEB1 in which this region was deleted (ZEB1 DNTR ) and examined its capacity to repress the E-cadherin promoter. Like ZEB1 CIDm with respect to CtBP, elimination of the BRG1-binding site reduced the repressor capacity of ZEB1 DNTR (Figure 5a ).
ZEB1 only represses transcription when directly recruited to DNA. We therefore reasoned that overexpression of the NtR of ZEB1 should bind and titrate out endogenous BRG1, thus preventing its interaction with ZEB1 bound to the E-cadherin promoter. Indeed, we found that overexpression of increasing amounts of NtR-but not an empty vector-efficiently blocked repression of E-cadherin by DNA-bound ZEB1 thus working as a dominant negative (Figure 5b ).
BRG1 regulates transcription by altering the nucleosome structure around genes, a configuration that is not, however, fully replicated in transient transfection experiments. Previous studies have found that stable integration of a promoter reporter construct into chromatin enhances the capacity of BRG1 to activate/ repress transcription (Fryer and Archer, 1998; Zhang et al., 2000) . Therefore, we generated stable clones with the E-cadherin-luc reporter stably integrated into C33a cells. Although-as in transient experiments illustrated in Figure 4d -ZEB1 showed limited repressor activity of the integrated E-cadherin reporter in C33a; co-expression of BRG1 resulted in a much more efficient repression than in transiently transfected E-cadherin (Figure 5c ).
ZEB1 and BRG1 regulate the expression of the endogenous E-cadherin gene
In preceding sections, we have established BRG1 as a ZEB1 co-represssor in the regulation of the E-cadherin promoter. Next, we wondered whether ZEB1/BRG1 complexes also regulate endogenous E-cadherin protein. 
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To this end, we examined the effect of eliminating endogenous ZEB1 or BRG1 in SW480 colorectal cells, lacking basal E-cadherin expression and expressing high levels of ZEB1. If overexpression of ZEB1 induces an EMT, its elimination triggers a mesenchymal-epithelial transition, characterized by loss of mesenchymal characteristics in favor of an epithelial phenotype . We found that knocking down of BRG1 in SW480 cells using specific siRNAs was able to induce the de novo expression of the E-cadherin protein and the downregulation of endogenous vimentin (Figure 6a) .
In a reverse set of experiments in MCF7 cellsshowing opposing patterns of E-cadherin and ZEB1 expression than SW480-we examined whether ZEB1 requires BRG1 in the regulation of endogenous E-cadherin and vimentin (Figure 6b and Supplementary Figure F) . Indeed, elimination of endogenous BRG1 through siRNA diminished the ability of ZEB1 to 
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Genomic DNA E Cad-Luc Figure 5 (a) The NtR of ZEB1 is required for repression of the E-cadherin-luc. MCF7 cells were co-transfected with E-cadherin-luc along equal molar amounts of either ZEB1 DNTR or ZEB1 CIDm . Control vectors and transcriptional assays were included and assessed as referred in Figure 1. (b) The NtR of ZEB1 acts as a dominant negative of E-cadherin repression by ZEB1. MCF7 cells were cotransfected with E-cadherin-luc and ZEB1 as referred in Figure 4b . Where indicated increasing molar amounts of Gal4-NtR-ZEB1 (0.3, 0.6 and 1.8 mg)-unable to bind the E-cadherin promoter-were also co-transfected. The maximum amount of Gal4-NtR-ZEB1 did not have by itself any significant effect on the E-cadherin promoter (last bar on the right). (c) Enhanced corepressor activity of BRG1 over a stably integrated E-cadherin reporter. C33a clones with E-cadherin-luc stably integrated into the chromatin were transiently co-transfected with ZEB1 and/or BRG1 as in Figure 4d . Results are representative of four independent C33a clonal lines. Control vectors and transcriptional assays were included and assessed as in Figure 1 .
Repression of E-cadherin by ZEB1/BRG1 E Sánchez-Tilló et al regulate both genes-partially reverting the effect of ZEB1 in the repression of E-cadherin and the induction of a mesenchymal phenotype (Figure 6b and Supplementary Figure F) . In summary, these results indicate that BRG1 is an important cofactor of ZEB1 in its regulation of E-cadherin and the EMT process. 
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Discussion
The loss of E-cadherin in carcinomas is associated with increasing invasiveness and hence poorer clinical prognosis. Although a number of EcTRs (SNAI1, SNAI2, ZEB1, ZEB2, E12/E47, Twist1/2) have been identified the molecular mechanism(s) by which some of them operate remains yet to be elucidated. In this paper, we reported that BRG1 binds to the NtR of ZEB1 acting as its co-repressor in the regulation of the E-cadherin promoter. BRG1-mediated repression by ZEB1 is enhanced when the promoter is stably integrated into genomic DNA suggesting that ZEB1/BRG1 complexes may repress E-cadherin by remodeling the local structure of chromatin around the gene. We have provided evidence that ZEB1 and BRG1 colocalize in E-cadherin-negative cells in the stromal compartment of normal colon as well as in de-differentiated epithelial cells, characterized by nuclear b-catenin staining, at the invasive front of colorectal carcinomas. Impairing the binding of BRG1 to ZEB1 diminishes the latter's capacity to repress endogenous E-cadherin and induce vimentin in epithelial cells. A wealth of reports has inversely correlated expression of E-cadherin with that of ZEB1 and other EcTRs in primary tumors and cell lines. Nevertheless, the specific role of each EcTR in E-cadherin expression and EMT regulation remains unclear. EcTRs seem to be using distinct co-repressor mechanisms and it has been suggested that the availability of these co-repressors could dictate which EcTR is involved in a given tumor (Vandewalle et al., 2009) . However, the situation is likely to be more complex as binding between EcTRs and their co-repressors could be regulated by posttranslational modifications . The finding that ZEB1 and ZEB2 are regulated by SNAI1 also indicates the existence of hierarchical relations among EcTRs (Guaita et al., 2002; Beltran et al., 2008) . Furthermore, loss of E-cadherin could also induce ZEB1 and Twist in a self-reinforcing loop to maintain a mesenchymal state (Onder et al., 2008) .
ZEB1 expression is not only inversely correlated to E-cadherin but also to the K-ras dependency of epithelial tumors and the ability of K-ras to maintain cell viability-elimination of K-ras in K-ras-independent cancer cells only induces cell death when ZEB1 is depleted (Singh et al., 2009) . The same study links epithelial differentiation to a K-ras-dependent gene signature for pharmacological targets thus positioning EMT regulators as potential therapeutic targets (Singh et al., 2009 ).
Our results indicate that BRG1 synergizes with ZEB1 in repressing the E-cadherin and in initiating an EMT process. Loss-of-function brg1 mutations have been described in a number of tumors; in addition, gene deletion studies in mice have also shown a role of BRG1-but not BRM-in tumor development (Bultman et al., 2000; Kadam and Emerson, 2003; Glaros et al., 2008; Medina and Sanchez-Cespedes, 2008 ). However, it is possible that BRG1 could have different, or even opposing, roles depending on the tissue, the factors (oncogenic or anti-oncogenic) with which BRG1 interacts and/or the functional activity of various proteins within the SWI/SNF complex. For instance, while BRM expression is frequently lost in tumors affecting the alimentary tract (in particular gastric carcinomas), BRG1 is usually retained (Yamamichi et al., 2007) . In fact, BRG1 may act in an oncogenic manner in some tumors (Wang et al., 2009) . Furthermore, increased expression of BRG1 has been associated with tumor growth and invasiveness in prostate tumors (Sun et al., 2007) as well as higher metastatic behavior in gastric carcinomas (Sentani et al., 2001) . Although brg1 heterozygotes have higher incidence of tumors, it is worth noting that these are mostly differentiated epithelial tumors (Bultman et al., 2000) .
BRG1-and BRM-containing complexes regulate different set of genes during cellular proliferation and differentiation (Kadam and Emerson, 2003) . The fact that ZEB1 cooperates with the former but not with the latter could shed light onto the multiple roles of ZEB1 in gene regulation. BRG1 interacts with DNA-binding proteins (activators, repressors and general transcription machinery factors) to be recruited to specific gene promoters (Trotter and Archer, 2008) . In this study, we described BRG1 as a co-repressor of ZEB1. Although BRG1 is better known for its role in promoting transcriptional activation-via nuclear receptors, MEF2D, Smad3, STAT1/2-it also participates in gene silencing through its direct interaction with transcriptional repressors (Zhang et al., 2000; Burkhart et al., 2005) .
It is worth noting that all EcTRs co-repressors identified until now (for example, BRG1, CtBP, PRC2, Sin3a, NuRD) are part of chromatin-remodeling complexes potentially linking epigenetic and transcriptional mechanisms of E-cadherin regulation (BRG1 in this paper, Postigo and Dean, 1999a, b, 2000; Peinado et al., 2004 Peinado et al., , 2007 Herranz et al., 2008; Verstappen et al., 2008) . SWI/SNF complexes have been associated with demethylation of E-cadherin and CD44 genes (Banine et al., 2005) although interactions of SWI/SNF with At 48 h, cell lysates were loaded into polyacrylamide gels and protein levels were assessed by WB with the corresponding Abs as described in Supplementary Information. (b) BRG1 is required for efficient repression of endogenous E-cadherin and induction of EMT by ZEB1. MCF7 cells were transfected with an empty vector or ZEB1 along with pBABE-puro and either control siRNA or a siRNA specific to knock down BRG1. Upon puromycin selection, cells were analyzed for E-cadherin and vimentin expression by immunofluorescence-imposed over DAPI nuclear staining-in confocal microscopy. Expression of ZEB1 and BRG1 is shown here as controls while their corresponding nuclear DAPI stainings are in Supplementary Figure F . Size bar corresponds to 38 mm.
Repression of E-cadherin by ZEB1/BRG1 E Sánchez-Tilló et al methylated DNA could also induce transcriptional repression (Harikrishnan et al., 2005) . In our own knock down studies, elimination of BRG1 induced E-cadherin protein expression-most likely by relieving the repressor effect exerted by endogenous ZEB1-in an otherwise negative cell line. Future studies should determine whether BRG1 contributes to the repression of other ZEB1 target genes regulated by methylation.
In this study, we have defined the N-terminal region of ZEB1 as the BRG1-interacting domain, which differs from the CID region where CtBP binds. Although BRG1 and CtBP act as ZEB1 co-repressors independently of each other both are required for the efficient repression of E-cadherin. Given their additive effect in the downregulation of E-cadherin, it is tempting to speculate that CtBP and BRG1 contribute to ZEB1 targeting different transcriptional activators within the E-cadherin promoter. In that regard, it would be advantageous for ZEB1 to have different repressor mechanisms to regulate the E-cadherin (or other ZEB1 target genes) at different tissues, or differentiation stages.
Mounting evidence seems to indicate that expression of EcTRs may also vary within the tumor. Thus, in an orthotopic mouse model of pancreatic cancer SNAI1 is present in the center of the tumor while SNAI2 is expressed at the invasive front (Hotz et al., 2007) . Meantime, in adrenal tumors both SNAI1 and Twist are present in the periphery of the tumor (Waldmann et al., 2009) . Although well-differentiated tumors might still express E-cadherin, its loss is an essential condition for ulterior invasion into surrounding tissues and metastasis (Polyak and Weinberg, 2009) . Over 80% of colorectal carcinomas involve mutations of the APC tumor suppressor gene, which results in a lack of degradation and nuclear accumulation of b-catenin. At the tumor center, however, b-catenin shows a predominantly membranous/cytoplasmic distribution and is only found nuclear at the tumor invasive front in isolated de-differentiated E-cadherin-negative epithelial cells (Brabletz et al., 1998 (Brabletz et al., , 2002 , whose presence has been associated with poorer clinical prognosis (Baldus et al., 2004) . During tumor invasion, these nuclear b-catenin cells seem to be the first to undergo EMT and lose E-cadherin. ZEB1 is present neither in the epithelial cells of normal colonic mucosa nor the tumor center, but rather in those E-cadherin-negative de-differentiated cells containing nuclear b-catenin at the point in which it colocalizes with BRG1.
In conclusion, the results presented here have identified ZEB1/BRG1 as a new transcriptional mechanism in the repression of E-cadherin during EMT and tumor progression.
Materials and methods
Reagents, antibodies, plasmids and sequences
The various sources of plasmids, antibodies and sequences for primers and siRNAs are described in the Supplementary Information section.
Cells, cell cultures and human tissues
The origins of the cell lines used in this work are described under Supplementary Information. Cell lines were cultured in Dulbecco's modified Eagle's medium (Lonza, Basel, Switzerland) containing 10% fetal calf serum (Sigma, St Louis, MO, USA). Use of normal and tumor human samples was approved and followed the guidelines of the local clinical research ethics committee (Hospital Clinic, Barcelona, Spain).
Cell transfection and transcriptional assays Cells were transfected with expression or reporter vectors using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) or by using the calcium phosphate method . siRNA oligonucleotides were transfected at 50 nM using Lipofectamine RNAiMAX (Invitrogen). After 36 and 48 h, cells were processed for transcriptional or immunoprecipitation assays. In the former, the firefly luciferase activity of the E-cadherin promoter was assessed using a Luciferase Assay kit (Promega Corp., Madison, WI, USA). As an internal control of transfection efficiency cells were cotransfected with pCMV-b-gal (Clontech, Mountain View, CA, USA) and values were determined with a b-gal detection kit (Clontech). Clones of C33a stably carrying E-cadherin-luc were generated by cotransfecting the puromycin resistant vector pBABE-puro. After 15 days of puromycin selection (1 mg/ml) (Sigma), clones were isolated and tested.
Immunoprecipitation and western blot assays Immunoprecipitation and western blot assays were performed as previously described (Postigo et al., 1999c) . Briefly, cells were lysed in radioimmunoprecipitation assay buffer (150 mM NaCl, 1% NP40, 0.5% sodium dodecyl sulfate, 50 mM Tris pH8, 2 mM EDTA plus protease inhibitors). Wherein indicated lysates were immunoprecipitated with the corresponding primary Abs and protein A, and were then loaded onto 8% poly-acrylamide gels. Around 2.5% of the lysate was also directly loaded onto gels as input control for direct western blotting. Gels were then transferred to a PVDF membrane (ImmobilonP, Millipore, Bedford, MA, USA). After blocking (4% non-fat milk), membranes were incubated with the corresponding primary and horseradish peroxidase-conjugated secondary Abs before the chemiluminescence reaction was developed, using a Pierce ECL kit (Termo Fisher Scientific, Waltham, MA, USA).
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays were performed using the EpiQuick ChIP kit (Epigentek, Inc., Brooklyn, NY, USA) as per manufacturer's instructions. Rabbit polyclonal antiserum for ZEB1 and BRG1 and control rabbit IgG were used for immunoprecipitation (Supplementary Information). Promoter occupancy was assessed by 28 cycles PCR amplification of the À86/ þ 60 sequence of human E-cadherin (containing binding sites for ZEB1) using primers described in Vandewalle et al. (2005) .
Cell and tissue staining, immunofluorescence and confocal analysis SW480 cells and samples of normal and tumor colon tissues were fixed for 30 min with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA), and then permeabilized with phosphate-buffered saline-0.5% Triton X100 and 0.1% sodium borohydride (Sigma) for background reduction. After 1 h blocking, (5% primary antibody-matching normal serum plus 4% bovine serum albumin in phosphate-buffered saline, 0.5% Tween) cells were incubated overnight at 4 1C with the corresponding primary and secondary antibodies.
